Coronavirus hits America again
Pharmaceutical companies answer the latest outbreak in the United States with heavy research and development spending on new treatments.
Axmed
1 minute read
Pharmaceutical companies invest heavily in R&D in order to discover and develop new drugs that can be brought to market. The R&D process can be very expensive and time-consuming, often taking many years and requiring significant investment in clinical trials, regulatory compliance, and marketing. As a result, the cost of developing a new drug can run into billions of dollars.
Insights
Keep reading
Poor countries desperately need better access to generic medicines
Generic makers showed during the pandemic they can deliver low-cost treatments at scale. The Access to Medicine Foundation asks them to make it the rule.
From Financial Times, republished by the Access to Medicine Foundation
Pooled procurement of drugs in low- and middle-income countries can lower prices and improve access
Evidence from seven countries shows centralised public procurement cuts prices by around 15%, with smaller gains where the supply side is concentrated.
From VoxEU, CEPR
FDA grants accelerated approval for an Alzheimer's disease treatment
The U.S. Food and Drug Administration approves Leqembi (lecanemab) under its accelerated pathway, the second therapy targeting the underlying disease.
From U.S. Food and Drug Administration, via Alzheimers.gov